2025 United Kingdom Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 United Kingdom Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in the United Kingdom include Horizon Discovery Group plc, Amgen, Bicycle Therapeutics, and Congenica. Horizon Discovery Group plc is a key player offering gene editing and cell engineering services essential for immuno-oncology research, supporting drug discovery and development. Amgen operates a significant R&D center in Cambridge, UK, focusing on diverse aspects of drug development and regulatory affairs while collaborating closely with the National Health Service. Bicycle Therapeutics, headquartered in Cambridge, specializes in bicyclic peptides for precise cancer treatments, collaborating with global firms like Novartis. Congenica, another Cambridge-based firm, leverages genomic diagnostics and software-driven personalized medicine in cancer genetics and therapy development.
These companies benefit from the UK’s strong pharmaceutical regulatory framework, with approvals overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring safety and efficacy standards. The UK Government’s substantial health R&D investments support these companies with funding and infrastructure, creating a conducive environment for innovative pharmaceutical development. Additionally, the presence of numerous contract research organizations (CROs) and advances in AI and biotechnology contribute to the dynamic growth of the cancer immunotherapy drug discovery outsourcing market in the UK, projected to reach over USD 274 million by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in the United Kingdom include Horizon Discovery Group plc, Amgen, Bicycle Therapeutics, and Congenica. Horizon Discovery Group plc is a key player offering gene editing and cell engineering services essential for immuno-oncology research, supporting drug discovery and development. Amgen operates a significant R&D center in Cambridge, UK, focusing on diverse aspects of drug development and regulatory affairs while collaborating closely with the National Health Service. Bicycle Therapeutics, headquartered in Cambridge, specializes in bicyclic peptides for precise cancer treatments, collaborating with global firms like Novartis. Congenica, another Cambridge-based firm, leverages genomic diagnostics and software-driven personalized medicine in cancer genetics and therapy development.
These companies benefit from the UK’s strong pharmaceutical regulatory framework, with approvals overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring safety and efficacy standards. The UK Government’s substantial health R&D investments support these companies with funding and infrastructure, creating a conducive environment for innovative pharmaceutical development. Additionally, the presence of numerous contract research organizations (CROs) and advances in AI and biotechnology contribute to the dynamic growth of the cancer immunotherapy drug discovery outsourcing market in the UK, projected to reach over USD 274 million by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
